<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04105699</url>
  </required_header>
  <id_info>
    <org_study_id>AB-PSP-002</org_study_id>
    <nct_id>NCT04105699</nct_id>
  </id_info>
  <brief_title>Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis</brief_title>
  <official_title>A Multicenter, Prospective, Biomarker-result-blinded Observational Study Evaluating Immunoassay Measurements of Pancreatic Stone Protein Performed on Abionic's abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abionic SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Biomedical Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ocean State Clinical Coordinating Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abionic SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, biomarker-result-blinded observational study evaluating
      immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE
      device with the PSP assay on adult ICU patients at risk of sepsis as an aid in identifying
      sepsis. Participants will be followed for the development of infection and sepsis until
      discharge from ICU or death or until day 7 (or day 15 of ICU if participant diagnosed with
      ICU-acquired infection or sepsis during the first 7 days), whatever comes first.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ability of the abioSCOPE PSP assay performed on day 1 of a participant's ICU admission to correctly identify those with sepsis.</measure>
    <time_frame>Day 1</time_frame>
    <description>Assess the clinical sensitivity and specificity of the abioSCOPE PSP assay obtained on day 1 of ICU stay to identify sepsis, based on EIRC assessment of sepsis.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Diagnostic performance assessment of the abioSCOPE PSP assay performed on day 1 and daily, together with other laboratory data and clinical assessments, to correctly identify sepsis from infection-negative or infection-positive systemic inflammation</measure>
    <time_frame>Day 1 to Day 7 (or day 15 if ICU-acquired infection or sepsis during first 7 days) or until discharge from ICU</time_frame>
    <description>Sensitivity, specificity, positive and negative predictive values of the abioSCOPE PSP assay obtained on day 1 and daily up to day 7 (or day 15 if ICU-acquired infection or sepsis during first 7 days) of ICU stay to identify sepsis, based on EIRC assessment of sepsis.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">417</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Device: Blood sampling</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Daily blood sample which will be taken for the PSP measurement using the abioSCOPE as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein [CRP] and Procalcitonin [PCT]).</description>
    <arm_group_label>Device: Blood sampling</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      venous serum retained for future investigation related to sepsis biomarkers
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ICU admitted patients at risk of developing sepsis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Provision and understanding of signed and dated written informed consent by patient
             or legally designated representative prior to any mandatory study-specific procedures,
             sample collection, or analysis.

          -  2. Male or female, aged ≥ 18 years.

          -  3. Admitted to ICU on the day of screening, with expectation that patient will require
             ICU management for a minimum of 24 hours.

        Exclusion Criteria:

          -  1. Expected to die within 24 hours no matter what therapy is given, from the time of
             screening.

          -  2. Suffering on ICU admission or study entry from or known acute or chronic
             pancreatitis or pancreatic cancer).

          -  3. Admitted to ICU due to elective cardiac surgery with an uncomplicated stay
             anticipated.

          -  4. Patients having a valid Do Not Resuscitate order.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabien Rebeaud, PhD</last_name>
    <phone>+41213533380</phone>
    <email>fabien.rebeaud@abionic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurie Girard, MSc</last_name>
    <phone>+41213533380</phone>
    <email>laurie.girard@abionic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helen Donnelly</last_name>
      <phone>312-503-1097</phone>
      <email>h-Donnelly@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Wunderink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joyce Brown</last_name>
      <phone>312-942-6771</phone>
      <email>joyce_d_brown@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Balk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BayState Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Romain</last_name>
      <phone>413-794-4889</phone>
      <email>sarah.romain@baystatehealth.org</email>
    </contact>
    <investigator>
      <last_name>Mark Tidswell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Health St. Vincent</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Steinhauser, MD</last_name>
      <phone>419-251-4919</phone>
      <email>Tina_steinhauser@mercy.com</email>
    </contact>
    <investigator>
      <last_name>Luis Jauregui-Peredo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Palmisciano</last_name>
      <phone>401-444-4961</phone>
      <email>apalmisciano@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Mitchell Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Pancreatic Stone Protein</keyword>
  <keyword>Point-of-care device</keyword>
  <keyword>Immunoassay</keyword>
  <keyword>Intensive care unit</keyword>
  <keyword>Abionic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

